Citigroup Inc. raised its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Rating) by 3,677.1% during the fourth quarter, Holdings Channel reports. The firm owned 83,059 shares of the company’s stock after buying an additional 80,860 shares during the period. Citigroup Inc.’s holdings in Akero Therapeutics were worth $4,552,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the business. Belpointe Asset Management LLC acquired a new position in shares of Akero Therapeutics in the 4th quarter worth approximately $95,000. Swiss National Bank boosted its holdings in shares of Akero Therapeutics by 2.6% in the 4th quarter. Swiss National Bank now owns 71,000 shares of the company’s stock worth $3,891,000 after acquiring an additional 1,800 shares in the last quarter. Arizona State Retirement System acquired a new position in shares of Akero Therapeutics in the 4th quarter worth approximately $455,000. Handelsbanken Fonder AB acquired a new position in shares of Akero Therapeutics in the 4th quarter worth approximately $378,000. Finally, TD Asset Management Inc boosted its holdings in shares of Akero Therapeutics by 174.1% in the 4th quarter. TD Asset Management Inc now owns 52,422 shares of the company’s stock worth $2,873,000 after acquiring an additional 33,300 shares in the last quarter. 97.76% of the stock is owned by institutional investors and hedge funds.
Akero Therapeutics Stock Performance
Shares of Akero Therapeutics stock opened at $45.60 on Friday. The firm has a fifty day moving average of $41.75 and a two-hundred day moving average of $44.22. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -16.70 and a beta of -0.94. Akero Therapeutics, Inc. has a 52 week low of $7.52 and a 52 week high of $54.88. The company has a debt-to-equity ratio of 0.08, a quick ratio of 18.61 and a current ratio of 20.83.
Insider Buying and Selling at Akero Therapeutics
Analyst Ratings Changes
AKRO has been the topic of several recent analyst reports. Morgan Stanley raised Akero Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $40.00 to $65.00 in a report on Friday, January 27th. Lifesci Capital restated an “outperform” rating on shares of Akero Therapeutics in a research report on Tuesday, April 11th. HC Wainwright dropped their price objective on shares of Akero Therapeutics from $64.00 to $62.00 in a research report on Tuesday, May 16th. Finally, Canaccord Genuity Group boosted their price objective on shares of Akero Therapeutics from $50.00 to $58.00 and gave the stock a “buy” rating in a research report on Tuesday, March 21st. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $52.00.
Akero Therapeutics Company Profile
Akero Therapeutics, Inc is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm’s lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
- Get a free copy of the StockNews.com research report on Akero Therapeutics (AKRO)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Want to see what other hedge funds are holding AKRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Rating).
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.